BMRA: Biomerica, Inc Price Chart

Biomerica, Inc - graphic logo of issuer BMRA

Biomerica, Inc. (BMRA) develops automated diagnostic systems for gastrointestinal pathologies that eliminate the need for manual labor. US-based test production capacities ensure supply reliability through a diversified portfolio. This price chart, with a value of 1.31, clearly demonstrates the asset's price action. The business relies on patent protection and strict FDA requirements, which create high barriers to entry for new players.

Price Performance Chart: Biomerica Inc (BMRA) for 07/04/2022 - 11/17/2026

Metric breakdowns and analytics for Biomerica, Inc (BMRA)

- stock quotes and analyst forecast:
Analysis of all company metrics:Biomerica, Inc
Signature product of Biomerica Inc.

Investors assess capital risks through market value, which aggregates all of the company's internal processes into a single cash equivalent. Given the FDA's strict oversight of Biomerica, Inc. home tests, this price chart reflects the balance between the success of the InFoods system and regulatory barriers, allowing for a real-time assessment of asset management efficiency through quote volatility.